C hronic wounds impose a significant burden on patients, society and healthcare providers.
1,2 A chronic wound has been defined as a wound that has not healed within three weeks of onset. 3 Based on this definition it is reasonable to include acute wounds that have not healed within three weeks, bearing in mind that there is a similar failure of the wound to proceed through an orderly and timely healing process.
The financial costs of wound to the NHS are considerable. A recent and comprehensive health economic evaluation of the burden of wounds has estimated a yearly cost of £5.3 billion to the NHS. 4 Wound infection occurs in the presence of multiplying bacteria in body tissues. It is not bacterial presence per se that causes infection but the microbial expression of virulence factors that results in tissue damage 5 and delayed healing. 6, 7 The host response is commonly inflammation that is easily recognised in the acute wound through the manifestation of redness, swelling, heat and pain. 8 In chronic wounds, more subtle signs of infection have been characterised. 9 These diagnostic criteria have been validated 10 and more recently wound-type specific criteria have also been developed. 11 Treatment of wound infection needs to be prompt and effective if increased morbidity is to be avoided. The widespread misuse of antibiotics together with concerns over the emergence of resistant bacteria 12 are well documented and provide a platform for the development and introduction of effective potent topical therapeutics that are broad-spectrum yet avoid inducing microbial selection for resistance. 13 Surgihoney RO (SHRO) is a licensed CE marked sterile topical antimicrobial that has been shown to be a potent antimicrobial in vitro, 14, 15 active against Grampositive and Gram-negative bacteria, including multidrug resistant (MDR) strains. It is effective in acute and chronic wound infection, in the prevention of surgical wound infection, 16, 17 in reducing and preventing intravascular line site colonisation 18 and against biofilm-encased bacteria. 19 SHRO is a pure honey-derived
bioengineered product that was initially developed as a wound care therapy, but may have other clinical applications for the control of bacteria and biofilms on mucosal surfaces and in cavities. It is pure in that it contains no antibiotic residues or agricultural additives, but has undergone a process to enhance its natural antimicrobial activity. 15 During the engineering process the production and activity of the active agent, reactive oxygen species (ROS), which includes hydrogen peroxide (H 2 O 2 ), is enhanced, resulting in a highly potent antimicrobial agent that is effective against a wide range of bacteria and fungi, 15 is nontoxic to human tissue, 14 and delivers ROS over a prolonged period.
14 As a simple treatment it can be applied in all areas of health care from first world critical care units to third world budget rural clinics.
Study aim
To assess the efficacy of SHRO in the healing process of wounds and in the reduction of bacterial load and inflammatory material associated with biofilm.
Methods
The evaluation design comprised prospective assessment of cases from a number of clinical centres in an international setting. The observation period for each patient varied. Ethics committee approval was not required as this assessment was of a CE-marked medical device (dressing) for use by qualified personnel as intended and is available commercially. All patients provided verbal consent to participate in this evaluation and to wound photography.
Data were collected and stored on a handheld tablet in an encrypted database that was uploaded electronically to a central secure database. Dressings and SHRO gel were changed at the discretion of the attending clinician and patient circumstances, but the recommendation was for gel change every 2-3 days. The gel is applied to the wound bed in an even layer up to approximately 2mm thick and covered with a suitable sterile secondary dressing. If the wound was heavily exuding it is advised to use a highly absorbent secondary dressing to avoid the gel being sluiced from the wound.
Results
A total of 114 wounds/104 patients were recruited. Of these, 84 patients (81%) were from four secondary care hospitals and three general practice surgeries in England and 20 patients (19%) from countries in the developing world (Table 1) .
A range of wound types were included, these together with the number of wounds, mean patient age, average wound duration and number of comorbidities are presented in Tables 2. Across all wound types the mean age of the patients was 61 years old (range: 32-91). The highest number of patients was the leg ulcer cohort. This group also had the highest mean age of patients (78 years old) and the longest mean wound duration at 8 months.
On enrolment, 109 wounds were recorded as deteriorating and five wounds were static. At the end of the evaluation period, all wounds were recorded as having improved following treatment with SHRO with 24 wounds (21%) closed (re-epithelialised).
The duration of treatment with SHRO varied from patient to patient as did the observation period. Treatment with SHRO ranged from 1 to 19 weeks, the mean duration being 25.7 days.
The type and level of exudate was identified as a clinical problem in 47 (41%) wounds. Following treatment the type of exudate changed from (unhealthy) green-tinged or purulent/haemopurulent/seropurulent, to clear serous exudate in all 47 wounds. Likewise, the level of exudate calculated semi-quantitatively as heavy or moderate at the start of treatment resolved to low/negligible in all 47 wounds.
The wound type and associated changes in wound pain are seen in Table 3 . A clear decrease in pain between the beginning and end of the evaluation period was recorded in 54 patients.
In this evaluation the presence of slough, necrotic material and increasing exudate was equated with a raised suspicion of the presence of biofilm. A total of 41 wounds were initially recorded as having slough or necrotic tissue present. The breakdown of wound type and debridement outcomes are seen in Table 4 and illustrated in Fig 1 and 2 . In this evaluation debridement was achieved through larvae therapy in two patients, sharp debridement in three patients and through the topical application of SHRO in conjunction with a simple retentive dressing in all remaining evaluation patients (Table 4) .
It is not known why the quantity of slough increased in one patient in the PU group. Nonetheless, by day 22 wound size had decreased by 60% and the wound was recorded as 'progressively healing'. Overall the results indicate excellent debridement and possible biofilm reduction following use of SHRO The majority of wounds treated with SHRO were noted to have reduced in size and shown positive improvement towards wound healing criteria. These criteria were observed in conjunction with reduction in the level of wound exudate, pain, slough and inflammation (Table 5) . A total of 40 wounds from patients resident in England had serial microbiological sampling. A reduction in bacterial load was demonstrated in 39 (98%) of the wounds. The number of swabs taken according to wound type may be seen in Table 5 . 
M A H E A LT H C A R E LT D
SHRO treatment was very well tolerated. Patients were asked to report adverse effects at each dressing change; the majority (102/104) patients reported no adverse effects at all with SHRO treatment, two reported stinging, one with a chronic venous ulcer refused any further SHRO treatment on day 4 and was withdrawn from the evaluation. There were two other patients with severe comorbidities who did not report adverse effects while being treated with SHRO, but died as a result of other causes during treatment: one due to left ventricular cardiac failure, the other due to organ failure with widespread malignancy.
Discussion
Many of the patients included in this evaluation had multiple comorbidities. These patients and their wounds present a challenge to the clinicians in terms of achieving progression to healing.
It is widely accepted that wound infection causes pain 20 and that there are established links between wound pain, stress, delayed healing and patient quality of life. 21 Achieving a reduction in wound pain following application of a topical antimicrobial agent is a positive indication the reduction in pain following application with SHRO is consistent with earlier reports. 17, 22 Recent fi ndings indicate that when sharp debridement is regularly performed the chance of healing increases 2.5-fold. 23 However the precise relationship between slough, infection and biofi lm is still being investigated. In a rat model, infection was associated with slough, necrotic tissue and wound pocketing. All these features delayed healing compared with a control or colonised group. 24 Other reports show that when wounds become colonised with bacteria that can form biofi lms, healing is delayed. 25, 26 The effi cacy of SHRO in the reduction of wound biofi lm has already been demonstrated in vitro. 19 When attempting to establish if there are clinical signs of biofi lm in wounds the fi ndings are more tenuous, particularly without a biopsy of the wound for histological examination. An increase in the level of exudate, failure of wound closure despite appropriate therapy, build up of slough despite debridement and the presence of the subtle signs of infection have been proposed. 27 In addition a glazed/shiny/translucent appearance of the wound bed has also been suggested. 28 Although these latter signs are clinically related to delayed wound healing a robust validation relating these to the presence of biofi lm has yet to be undertaken.
Topic antimicrobial preparations are available to treat or prevent wound infection. Silver impregnated dressings appear to possess good localised antimicrobial activity; 29 however, they also display cytotoxicity compared with honey preparations. 30, 31 Iodine analogues also possess good antimicrobial 31-36 There is also increasing concern about the use of chlorhexidine preparations in wound dressings due to the development of antimicrobial resistance and toxicity. 37, 38 A Cochrane Collaboration report stated that honey may be superior to some conventional dressing materials, 39 but there is considerable uncertainty about the replicability and applicability of this evidence. This Cochrane review was compiled before the published evidence of efficacy with SHRO.
This evaluation supports the idea that SHRO helps clear the bacterial bioburden assessed by semi-quantitative culture. This possible biofilm reduction, as assessed through reduction of slough and necrotic material adhering to ulcer base, supports wound contraction, reduction in exudate, inflammation, pain, and facilitates debridement.
Evaluation limitations
This observational evaluation included subjective reporting. Sampling bias occurred naturally as the patients were 'enrolled' at the discretion of the clinician. There was neither randomisation nor control of treatment. The patients' wounds and conditions were highly varied. Furthermore, biofilm is difficult to assess without histological biopsy and so a reduction in biofilm was assumed to occur by reduction in slough and necrotic material. Bacterial culture assessments were semi-quatitative and were not undertaken in every patient.
Further possible benefits from SHRO gel that are difficult to measure in this evaluation but are important aspects of wound healing could be wound deodorisation, stimulation of tissue growth, synthesis of collagen, stimulation of development of new blood vessels and nerve endings in the bed of wounds. Further research is being undertaken to establish this.
Recommendations
The clinical use of a topical antimicrobial, on skin, in wounds and cavities and possibly on other mucosal surfaces and internal structures at surgery, both to prevent infection and treat low grade localised infection Other topical infections 3 3 n/a n/a n/a n/a 
Conclusions
This evaluation reports positive outcomes on 104 patients with 114 wounds who received topical SHRO gel as a treatment in a wide range of chronic wounds, line sites, surgical and traumatic wounds.
The report shows that 24 wounds healed and 90 wounds improved within the evaluative period.
There was a positive reduction in wound pain, exudate production, devitalised tissue, wound bacterial load as assessed by reduction of slough and necrotic material. The dressing was well tolerated by the patients and shows much promise as an effective topical antimicrobial dressing in challenging wounds.
